Loading...
XKRX
063160
Market cap86mUSD
May 20, Last price  
21,900.00KRW
1D
-1.13%
1Q
4.29%
Jan 2017
-2.36%
Name

CKD Bio Corp

Chart & Performance

D1W1MN
XKRX:063160 chart
P/E
13.81
P/S
0.70
EPS
1,586.02
Div Yield, %
—
Shrs. gr., 5y
1.35%
Rev. gr., 5y
4.60%
Revenues
171.76b
+7.11%
66,409,841,00083,393,222,000106,553,579,000121,568,352,000110,527,721,450113,759,577,680100,370,797,420106,389,740,550106,690,657,800113,013,402,140118,187,072,160124,510,019,000137,184,188,550124,599,959,410142,238,418,400156,042,327,040160,352,778,354171,756,008,720
Net income
8.70b
P
-3,273,392,0008,737,629,00016,183,929,00014,375,712,00010,920,596,3707,101,290,0801,657,448,850-1,105,050,1406,653,133,0009,434,614,7508,016,298,6207,956,187,16012,264,879,9606,207,398,430-6,576,601,340-16,702,615,620-24,192,519,6408,700,827,330
CFO
14.03b
P
408,087,00010,689,037,00026,573,028,00023,887,459,00012,963,470,55022,900,061,37010,924,090,05011,222,959,39014,338,941,94015,500,000,86020,445,524,66015,535,533,73016,990,277,0004,824,020,040-5,882,180,150-3,204,562,880-7,223,883,84414,031,126,380
Dividend
Dec 29, 2021100 KRW/sh
Earnings
Jul 24, 2025

Profile

CKD Bio Corp. manufactures and distributes drug substances based on fermentation, synthesis, and biotechnology in South Korea. It offers drug substances in the areas of antibiotic, ß-lactamase inhibitors, immunosuppressants, anticancer drugs, obesity treatment drugs, dry eye, antivirus, antituberculosis, antihyperlipidemics, and probiotics. The company also provides contract research and development, and manufacturing services for active pharmaceutical ingredients and intermediates, and probiotics. It also exports its products. The company was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.ckdbio.com/
IPO date
Dec 11, 2001
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
171,756,009
7.11%
160,352,778
2.76%
156,042,327
9.70%
Cost of revenue
154,831,399
174,613,369
163,820,374
Unusual Expense (Income)
NOPBT
16,924,610
(14,260,591)
(7,778,046)
NOPBT Margin
9.85%
Operating Taxes
515,273
(4,098)
(1,887,245)
Tax Rate
3.04%
NOPAT
16,409,337
(14,256,492)
(5,890,801)
Net income
8,700,827
-135.96%
(24,192,520)
44.84%
(16,702,616)
153.97%
Dividends
(548,596)
Dividend yield
0.42%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
70,879,865
76,503,299
57,015,206
Long-term debt
61,482,635
72,133,718
84,162,321
Deferred revenue
Other long-term liabilities
2,308,197
1,697,436
1,171,986
Net debt
129,264,040
142,700,107
134,518,061
Cash flow
Cash from operating activities
14,031,126
(7,223,884)
(3,204,563)
CAPEX
(3,360,575)
(10,778,381)
(7,230,209)
Cash from investing activities
(4,753,342)
(1,195,570)
(20,546,514)
Cash from financing activities
(11,813,895)
7,402,421
24,959,279
FCF
21,300,723
(5,046,533)
(5,883,573)
Balance
Cash
1,164,200
3,699,770
12,724,497
Long term investments
1,934,260
2,237,140
(6,065,030)
Excess cash
Stockholders' equity
101,907,807
93,523,095
120,214,873
Invested Capital
264,524,294
271,648,591
287,896,838
ROIC
6.12%
ROCE
6.39%
EV
Common stock shares outstanding
5,486
5,486
5,486
Price
22,000.00
-7.76%
23,850.00
0.21%
23,800.00
-43.06%
Market cap
120,691,120
-7.76%
130,840,146
0.21%
130,565,872
-43.06%
EV
249,955,160
273,540,253
265,083,933
EBITDA
33,611,022
3,317,010
10,160,213
EV/EBITDA
7.44
82.47
26.09
Interest
5,266,840
4,988,555
2,938,333
Interest/NOPBT
31.12%